inTRAvent Medical Partners

Hershey, PennsylvaniaFounded 20151–10 employeesintraventmedical.comLinkedIn

inTRAvent Medical Partners LP is a privately held medical device company developing bedside intra-operative imaging and navigation technologies for neurosurgery. Its first product, the FDA-cleared SOLOPASS system, assists with precision planning and guidance during frontal placement of intraventricular catheters.

Visit intraventmedical.com ↗

Founded: 2015
Employees: 1–10

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

inTRAvent’s most significant recent milestone was the November 18, 2025 publication of a landmark bench study evaluating the FDA-cleared SOLOPASS 2.0 ultrasound-guided neuronavigation system. The study reported a dramatic improvement in ventricular catheter placement accuracy, reinforcing the company’s focus on a common and lifesaving neurointensive-care procedure. On June 17, 2025, Dr. Adam S. Arthur joined as Chief Clinical Strategy Officer, adding neurosurgical expertise to clinical planning and product development. The company had previously appointed Dr. Kevin Foley Chief Innovation Officer on October 17, 2023. These appointments indicate an effort to strengthen both clinical validation and innovation leadership around its catheter-navigation platform. inTRAvent also has two granted patents and two registered trademarks, while a patent application covering a fixture for securing and assisting frontal surgical-equipment placement was published in 2023.

Market position

inTRAvent operates in a specialized segment of medical devices focused on image-guided neurosurgical procedures. Its differentiation is the combination of a portable bedside system, 2D and 3D ultrasound imaging, artificial-intelligence support, and trajectory guidance for intraventricular catheter placement. SOLOPASS is designed for a specific neurocritical-care workflow rather than broad operating-room navigation, which may allow the company to address a clearly defined procedural problem while keeping its initial product scope focused. Its likely competitive context includes established neurosurgical navigation and intra-operative imaging manufacturers, but no specific companies are included here. The company’s clinical leadership additions—Dr. Adam S. Arthur in 2025 and Dr. Kevin Foley in 2023—support an emphasis on physician-led product development. Its FDA-cleared status and reported 2025 bench-study results provide evidence of technical validation, although market adoption, installed base, pricing, and comparative clinical outcomes remain undisclosed.

Growth & opportunities

inTRAvent was founded in 2015 and has developed from a small medical-device venture into a focused neuro-navigation company with a defined lead product, SOLOPASS. The product combines portable 2D and 3D ultrasound, artificial intelligence, and trajectory guidance to support frontal intraventricular catheter placement. A key inflection point was the product’s FDA clearance, followed by the November 18, 2025 publication of bench-study results reporting substantially improved ventricular catheter-placement accuracy. Leadership expansion has accompanied this product-development phase: Dr. Kevin Foley became Chief Innovation Officer in October 2023, and Dr. Adam S. Arthur joined as Chief Clinical Strategy Officer in June 2025. The company remains small, with an employee range of one to ten, and no layoffs are reported. There is no disclosed funding history, valuation, investor base, revenue information, or employee-growth series, limiting assessment of financial scale and commercialization velocity. The next measurable trajectory indicators would be broader clinical evidence, hospital adoption, additional regulatory clearances, and growth in the operating team.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes inTRAvent Medical Partners distinct

reccy insights

What makes inTRAvent Medical Partners distinct

01Brings intra-operative imaging and navigation capabilities directly to the neurosurgical bedside.
02Developed technology originating at Penn State Hershey Medical Center.
03SOLOPASS is FDA-cleared for aiding frontal placement of intraventricular catheters.
04Combines medical-device leadership with expertise from neurosurgeons, neurocritical-care specialists, and clinical strategy advisors.
05Focuses on improving precision in a common and lifesaving neurointensive-care procedure.

Technology & products

SOLOPASS®
A portable neuro-navigation system using 2D and 3D ultrasound imaging and artificial intelligence for intra-procedural localization and navigation during intraventricular catheter placement.

SOLOPASS® portable neuro-navigation system
Bedside intra-operative imaging and navigation
2D and 3D ultrasound imaging
Artificial-intelligence-assisted procedural guidance
Ventricular-system visualization for intraventricular catheter placement

Recent updates2

Launches, partnerships and team changes from press coverage

Jun 17, 2025Team change
Dr. Adam S. Arthur was appointed Chief Clinical Strategy Officer, bringing neurosurgical expertise to clinical strategy and product development.
citybiz.co
Oct 17, 2023Team change
Dr. Kevin Foley was appointed Chief Innovation Officer.
businesswire.com

About inTRAvent Medical Partners

Products: SOLOPASS®
Leadership: Adam Arthur, Chief Clinical Strategy OfficerKevin Foley, Chief Innovation OfficerAdam Barner, Chief Executive Officer & Founder
Focus areas: Medical devices, neurosurgery, neurocritical care, surgical navigation, intra-operative imaging, healthcare, clinical technology, FDA-cleared devices
Headquarters: Hershey, Pennsylvania
Founded: 2015
Employees: 1–10
Patents granted: 2 (Crunchbase)
Trademarks: 2